These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7870368)

  • 41. Relevance of QT dispersion in haemodialysis patients.
    Di Iorio B
    Nephrol Dial Transplant; 2010 Apr; 25(4):1357-9; author reply 1360. PubMed ID: 20130305
    [No Abstract]   [Full Text] [Related]  

  • 42. Does the modality of haemodialysis treatment affect lipoprotein composition?
    Blankestijn PJ; Joles JA; Koomans HA
    Nephrol Dial Transplant; 1996 Jan; 11(1):14-6. PubMed ID: 8649622
    [No Abstract]   [Full Text] [Related]  

  • 43. Ocular findings in patients with chronic renal failure undergoing haemodialysis.
    Vrabec R; Vatavuk Z; Pavlović D; Sesar A; Cala S; Mandić K; Bućan K
    Coll Antropol; 2005; 29 Suppl 1():95-8. PubMed ID: 16193686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients.
    Chan D; Irish A; Croft KD; Dogra G
    Nephrol Dial Transplant; 2006 Jan; 21(1):234-5. PubMed ID: 16204285
    [No Abstract]   [Full Text] [Related]  

  • 45. [Dialysis treatment of chronic renal failure].
    Thieler H
    Zentralbl Chir; 1993; 118(3):118-21. PubMed ID: 8484283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Ascites in hemodialyzed patients].
    Szylman P; Shasha S; Tuma S; Chaimovitz S; Better OS
    Harefuah; 1975 Apr; 88(8):356-9. PubMed ID: 1140711
    [No Abstract]   [Full Text] [Related]  

  • 47. [The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure].
    Diadyk AI; Bagriĭ AE; Lebed' IA; Iarovaia NF; Shchukina EV; Gaĭdukov VO; Gritsenko PV; Diadyk IA
    Ter Arkh; 1997; 69(6):24-7. PubMed ID: 9297267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical impact of residual function in haemodialysis.
    Carofei O; Galeotti P; Satriani M; Pedulla F; Taratufolo A
    EDTNA ERCA J; 1997; 23(3):54-6. PubMed ID: 9664012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ascites in patients treated with maintenance hemodialysis.
    Wang F; Pillay VK; Ing TS; Armbruster KF; Rosenberg JC
    Nephron; 1974; 12(2):105-13. PubMed ID: 4600536
    [No Abstract]   [Full Text] [Related]  

  • 50. [Sequential ultrafiltration/hemodialysis for dialysis-associated ascites].
    Alon U; Chaimovitz C; Szylman P; Better OS
    Harefuah; 1979 Dec; 97(11-12):283-4, 324. PubMed ID: 16296106
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of enalapril on renal function in patients with severe chronic kidney disease.
    Vernaglione L
    Nephrol Dial Transplant; 2007 Feb; 22(2):665-6. PubMed ID: 16951420
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter?
    Grooteman MP; Nubé MJ
    Nephrol Dial Transplant; 2004 Dec; 19(12):2965-70. PubMed ID: 15507481
    [No Abstract]   [Full Text] [Related]  

  • 53. [Lung abscesses in patients on haemodialysis (author's transl)].
    Gasparović V; Ivanović D
    Lijec Vjesn; 1981; 103(2-3):67-9. PubMed ID: 7311703
    [No Abstract]   [Full Text] [Related]  

  • 54. Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.
    Guidi E; Minetti EE; Cozzi MG
    J Renin Angiotensin Aldosterone Syst; 2002 Mar; 3(1):40-5. PubMed ID: 11984747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Problems about the management of active pulmonary tuberculosis patients undergoing haemodialysis--our experiences and nation-wide questionnaire survey].
    Tomioka H; Tada K; Ohyama A; Fujiyama R; Ohnishi H; Sakurai T; Sakamoto H; Nishiguchi H; Yamamoto T; Sakashita T; Shirai C; Iwasaki H
    Kekkaku; 2003 Apr; 78(4):353-8. PubMed ID: 12739395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
    Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
    Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Unusual metabolic alkalosis in chronic renal failure].
    Thoreux PH; Chevet D; Le Pogamp P; Gie S; Rivalan J
    Ann Med Interne (Paris); 1986; 137(7):601-2. PubMed ID: 3813304
    [No Abstract]   [Full Text] [Related]  

  • 58. [Nephrogenic ascites. A case report].
    Elloumi H; Arfaoui D; Zayane A; Ajmi S
    Ann Med Interne (Paris); 2002 Nov; 153(7):478-80. PubMed ID: 12598834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Enoxaparin in haemodialysis].
    Olszowska A; Zelichowski G
    Pol Merkur Lekarski; 2002 Nov; 13(77):433-6. PubMed ID: 12621768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin converting enzyme inhibitor and chronic renal failure.
    Sitprija V; Lumlertgul D
    J Med Assoc Thai; 1993 Jul; 76(7):359-67. PubMed ID: 8089635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.